Valuation: Arcus Biosciences, Inc.

Market Cap 3.86B 3.31B 3.1B 2.83B 5.32B 370B 5.39B 36.58B 14.27B 186B 14.51B 14.19B 614B P/E 2026 *
-8.48x
P/E 2027 * -8.42x
Enterprise Value 3.42B 2.93B 2.74B 2.51B 4.71B 327B 4.77B 32.41B 12.64B 165B 12.85B 12.57B 544B EV / Sales 2026 *
43.5x
EV / Sales 2027 * 72.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
1 week+2.92%
Current month+7.63%
1 month+1.23%
3 months+29.49%
6 months+59.77%
Current year+27.32%
1 week 28.92
Extreme 28.9233
31.28
1 month 26.19
Extreme 26.19
31.28
Current year 18.52
Extreme 18.515
31.74
1 year 10.07
Extreme 10.07
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 72 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Sell

Founder

-20,067 0.0160%
6/11/26 A Free

Director

22,600 0.0180%
1/23/26 A Free

Chief Financial Officer

157,000 0.1269%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%+2.92%+188.13%+61.30% 3.86B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.68%+4.28%+94.77%+119.09% 28.03B
Weighted average by Cap. +0.52%+4.69%+100.87%+145.05%

Financials

2026 *2027 *
Net sales 78.61M 67.34M 63M 57.67M 108M 7.52B 110M 744M 290M 3.78B 295M 289M 12.5B 52.08M 44.61M 41.74M 38.21M 71.71M 4.98B 72.65M 493M 192M 2.5B 196M 191M 8.28B
Net income -451M -386M -361M -331M -621M -43.15B -629M -4.27B -1.67B -21.68B -1.69B -1.66B -71.7B -451M -387M -362M -331M -621M -43.18B -630M -4.27B -1.67B -21.69B -1.69B -1.66B -71.74B
Net Debt -441M -377M -353M -323M -607M -42.16B -615M -4.17B -1.63B -21.18B -1.65B -1.62B -70.05B -102M -87.51M -81.88M -74.95M -141M -9.77B -143M -967M -377M -4.91B -384M -375M -16.24B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
21/08/26 $30.34 +2.78% 1,055,172
20/08/26 $29.52 -2.73% 1,546,249
19/08/26 $30.35 +2.85% 1,816,243
18/08/26 $29.51 -0.17% 896,392
17/08/26 $29.56 +0.27% 2,174,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.34USD
Average target price
38.33USD
Spread / Average Target
+26.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock